Many of them include IFN-Ɣ-related genes, such as the 18-gene TIS associated with objective response and PFS after pembrolizumab in the KEYNOTE-028 trial [16], the 8-gene “T-effector and IFN-Ɣ signature” associated with overall survival (OS) after atezolizumab in 115 NSCLC patients in the POPLAR study [20], or the 4-gene “IFN-Ɣ signature” associated with objective response and PFS after durvalumab in 97 NSCLC patients [21]. This evidence concerns the gene IFNA1 and non-small cell lung carcinoma.